Media.Player

Nanoporphyrin Nanoparticles for Combination Phototherapy and Drug Delivery to Infantile Hemangiomas

Technology Benefits

Minimally invasive Tissue specific Fewer systemic side effects compared to other treatments Double therapeutic action of photodynamic therapy and propranolol

Technology Application

Infantile hemangiomas and other vascular malformations

Detailed Technology Description

Infantile hemangiomas are benign, vascular tumors of childhood affecting 5-10% of all infants, with lesions appearing shortly after birth and growing rapidly to cause potential disfigurement, functional loss, or even life-threatening complications in a significant proportion of patients. Surgical treatment of IH is difficult because of the highly vascular nature of the tumors, and current non-surgical treatment modalities are far from curing the disease. There is thus a need for non-invasive, high efficacy methods for the treatment of IH. Researchers at the University of California, Davis have developed a novel treatment method for IH that combines photodynamic therapy and the therapeutic compound propranolol using nanoporphyrin nanoparticles. Proof of concept studies in a reproducible mouse model have shown that photodynamic therapy delivered by nanoporpyhrin nanoparticles is effective in ablating IH tumors. When injected into mice, nanoporphyrin nanoparticles accumulate in IH tumors and are triggered by laser light to produce reactive oxygen species that destroy vascular cells in IH. Additionally, propranolol can be loaded into nanoporphyrin nanoparticles, and when triggered by laser light nanoparticles, release propranolol in IH creating a second treatment effect. Researchers are expecting that this combined treatment will be more effective than the existing methods in the treatment of IH. Because of its minimally invasive, tissue-specific nature, this composition has the potential for delivering higher levels of therapeutic to IH tumors with fewer systemic side effects while preventing the disfiguring consequences of IH.

Others

Additional Technologies by these Inventors

• Ligands for Alpha-4-Beta-1 Integrin
• Three-Dimensional Cell Adhesion Matrix
• A Novel RGD-Containing Cyclic Peptide for use in Cancer Imaging and as a Targeted-Therapy Ligand
• Functional Illumination in Living Cells
• Nanoparticles for Drug Delivery, Tissue Targeting and Imaging Analysis
• Early Detection of Ovarian Cancer Using Markers to Short Chain Carbohydrates
• PVA Nanocarrier System for Controlled Drug Delivery
• Site-Specific Ligation and Compound Conjugation to Existing Antibodies
• Novel Solid Tumor Chemodrug LLS2
• High Throughput Label-Free One-Bead-One-Compound (OBOC) Screening Assay
• Ligands for Improved Angiogenesis and Endothelialization of Blood Contacting Devices
• Proteoglycan Mimetics For Enhanced Wound Healing Angiogenesis And Vascular Repair

Tech ID/UC Case

25584/2015-761-0

Related Cases

2015-761-0

*Abstract

Researchers at the University of California Davis have developed a novel treatment method that combines photodynamic therapy and the therapeutic compound propranolol using a nanoparticle platform to treat infantile hemangiomas (IH).

*Principal Investigator

Name: Kit Lam

Department:

Name: Hakan Orbay

Department:

Name: David Sahar

Department:

Name: Yuanpei Li

Department:

Country/Region

USA